The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
|
5 min read
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
|
4 min read
More than 160 people with CF and their loved ones from across the country advocated for a more robust antibiotics pipeline during the CF Foundation's virtual March on the Hill.
|
3 min read
The Foundation’s award will support preclinical studies of a potential phage therapy to treat resistant Pseudomonas infections.
|
2 min read
White will be the first person living with CF to lead the Board into a new era of CF
|
5 min read
This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.
|
7 min read
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies
|
4 min read
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
|
1 min read
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
|
5 min read